Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - ObsEva (Details)

v3.24.0.1
Licensing and Other Arrangements - ObsEva (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 21, 2022
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Asset acquisition        
Impairment of intangible asset     $ 14,253  
Amortization expense     897 $ 97
Revenue recognized     2,650 4,150
Ebopiprant IP        
Asset acquisition        
Estimated useful life of intangible asset 17 years      
Impairment of intangible asset     $ 14,253  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income     Impairment charges (Note 4, Note 5)  
License Agreement | ObsEva, Organon        
Asset acquisition        
Maximum eligible milestone payments receivable $ 475,000      
Maximum earn-out payments 97,500      
Amortization expense     $ 900 100
Maximum earn-out payments for development and regulatory milestones 46,500      
Maximum earn-out payments for sales-based milestones 51,000      
License Agreement | ObsEva, Organon | Ebopiprant IP        
Asset acquisition        
Impairment of intangible asset   $ 14,200 $ 14,200 $ 0
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income   Impairment charges (Note 4, Note 5) Impairment charges (Note 4, Note 5)  
ObsEva IP        
Asset acquisition        
Cash payment at closing 15,000      
Cost to acquire assets 15,200      
Transaction costs $ 200      
Estimated useful life of intangible asset 17 years